Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT: TTFields (HeadG2) with radiation and temozolomide for newly diagnosed glioblastoma
jRCT2032220343Phase 3Active, not recruiting
- Sponsor
- NovoCure
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by NovoCure. Primary endpoint: Overall survival. Started Sep 2022; status: active, not recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2032220343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2032220343.